World Leader in Biomedical Materials Adds Three Renowned Experts to Board

DSM Biomedical, a global leader in biomedical materials, today announced the addition of three experts to its Scientific Advisory Board. Established in July 2007, the Board supports DSM Biomedical’s research and development strategy by advising on its scientific and technological quality, validity of hypotheses, and clinical relevance.

The newest members of the Biomedical Scientific Advisory Board include Samuel Stupp, James Kirkpatrick and Wouter Dhert, all leaders in the field of biomedical materials science. They join existing members Professor Tony Mikos, Dr. Ivo Buschmann, and Mr. Patrick Cahalan.

Dr. Samuel Stupp is a Board of Trustees Professor of Materials Science, Chemistry, and Medicine at Northwestern University (Chicago, USA), where he also serves as the Director for the Institute for BioNanotechnology in Medicine. He received this year an honorary doctorate from Eindhoven University for his pioneering work in complex molecular systems and their biomedical applications, and is the recipient of numerous awards and honors, including the Materials Research Society Medal Award and the American Chemical Society Award in Polymer Chemistry.

Dr. James Kirkpatrick is an expert in pathology and in vitro methods for biomaterial research and has authored nearly 350 articles in peer-reviewed journals on the topic. He has taught at universities across the globe and is currently Professor of Pathology and Chairman of the Institute of Pathology at Johannes Gutenberg University (Mainz, Germany). Dr. Kirkpatrick also serves as an external reviewer for several research councils and programs throughout Europe, as well as scientific journals, and was President of the European Society for Biomaterials from 2002-2007.

Dr. Wouter Dhert joins Drs. Stupp and Kirkpatrick, and brings almost 20 years of experience in translational orthopaedic research on biomaterials and tissue regeneration to DSM’s Biomedical Scientific Advisory Board. He is Professor of Translational Musculoskeletal Research, Director of Orthopaedic Research at the University Medical Center Utrecht, and part-time professor in Tissue Repair at the Faculty of Veterinary Medicine at Utrecht University (The Netherlands).

“With so many opportunities and interest in the biomaterials industry, it is vital to focus our resources in the areas that ultimately deliver the most benefits for as many patients as possible,” said Steve Hartig, President of DSM Biomedical. “We are honored to have such well-respected thought leaders join our Advisory Board, whose expert advice will help guide our efforts to advance medical technology through biomedical innovations.”

About DSM Biomedical
DSM Biomedical develops novel materials-based solutions to meet the present and future needs of the medical device and biopharmaceutical industries. Building on the expertise and strengths of DSM and its acquisition of DSM PTG (formerly The Polymer Technology Group), the company’s product portfolio includes coatings, drug delivery platforms and a wide range of biomedical materials for use in short- and long-term implantable medical devices. Key product brands include Bionate® PCU and CarboSil® TPU, two of the most extensively tested biomedical polymers ever developed. Both polymers have excellent biostability, high strength and abrasion resistance, making them candidate materials for load-bearing orthopedic implants. ComfortCoat™ hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems; and Dyneema Purity®, a high-performance polyethylene fiber technology developed specifically for use in medical applications, such as orthopedic implants. The company also markets the Trancerta™ family of bioresorbable materials for drug delivery. This portfolio is based on DSM’s core strengths in materials science combined with its extensive in-house library of synthesis methods, formulation and processing techniques. For more information, visit www.dsmbiomedical.com.

DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.